Answer
Ciprofloxacin inhibits CYP1A2 and significantly increases mexiletine hydrochloride exposure and the associated risk of adverse reactions, so clinical and ECG monitoring and dose adjustment may be indicated during and after ciprofloxacin treatment.
Sources for this answer
- Namuscla 167 mg hard capsulesLupin Healthcare (UK) Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked